User profiles for Alberto Tosetto
 | Alberto TosettoHematology Dept., S. Bortolo Hospital, Vicenza, Italy Verified email at aulss8.veneto.it Cited by 25793 |
[HTML][HTML] d-Dimer Testing to Determine the Duration of Anticoagulation Therapy
Background The optimal duration of oral anticoagulation in patients with idiopathic venous
thromboembolism is uncertain. Testing of d-dimer levels may play a role in the assessment of …
thromboembolism is uncertain. Testing of d-dimer levels may play a role in the assessment of …
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome
…, V De Micheli, A Ghirarduzzi, A Tosetto… - Blood, The Journal …, 2018 - ashpublications.org
Rivaroxaban is an effective and safe alternative to warfarin in patients with atrial fibrillation
and venous thromboembolism. We tested the efficacy and safety of rivaroxaban compared …
and venous thromboembolism. We tested the efficacy and safety of rivaroxaban compared …
Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis
Objective To determine the effect of sex on the risk of recurrent venous thromboembolism in
all patients and in patients with venous thromboembolism that was unprovoked or provoked (…
all patients and in patients with venous thromboembolism that was unprovoked or provoked (…
ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease
Background: von Willebrand disease (VWD) is a common inherited bleeding disorder. Significant
variability exists in management options offered to patients. Objective: These evidence-…
variability exists in management options offered to patients. Objective: These evidence-…
Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine
…, I Nichele, M Ruggeri, S Barra, A Tosetto - Internal and emergency …, 2021 - Springer
Currently, the SARS-CoV-19 pandemic represents the leading global health emergency, and
vaccines are the primary health strategy to eradicate this global challenge. In Europe, three …
vaccines are the primary health strategy to eradicate this global challenge. In Europe, three …
Congenital absence of the inferior vena cava: a rare risk factor for idiopathic deep-vein thrombosis
M Ruggeri, A Tosetto, G Castaman, F Rodeghiero - The Lancet, 2001 - thelancet.com
Congenital absence of the inferior vena cava (AIVC) is a rare vascular defect, commonly
reported as a fortuitous finding. The presence of AIVC in patients with DVT is underestimated …
reported as a fortuitous finding. The presence of AIVC in patients with DVT is underestimated …
Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group
In a previous publication on new terminology, definitions, and outcome criteria for immune
thrombocytopenia (ITP), the International Working Group (IWG) on ITP acknowledged that …
thrombocytopenia (ITP), the International Working Group (IWG) on ITP acknowledged that …
Patient-Level Meta-analysis: Effect of Measurement Timing, Threshold, and Patient Age on Ability of d-Dimer Testing to Assess Recurrence Risk After Unprovoked …
This article has been corrected. The original version (PDF) is appended to this article as a
supplement. Background: In patients with a first unprovoked venous thromboembolism (VTE), …
supplement. Background: In patients with a first unprovoked venous thromboembolism (VTE), …
Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for …
Background— Vitamin K antagonist (VKA) therapy is increasingly being used for the prevention
of venous thromboembolism and stroke in atrial fibrillation. Bleeds are the major concern …
of venous thromboembolism and stroke in atrial fibrillation. Bleeds are the major concern …
Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism
F Rodeghiero, A Tosetto - Annals of internal medicine, 1999 - acpjournals.org
Background: Resistance to activated protein C due to the factor V R506Q (Leiden) mutation
is the most common clotting abnormality in patients with venous thromboembolism. Objective…
is the most common clotting abnormality in patients with venous thromboembolism. Objective…
